Advanced search
Publication Cover
Modern Rheumatology Volume 18, 2008 - Issue 5
Journal homepage
20
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren’s syndrome

Tsuyoshi KasamaDivision of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, JapanCorrespondence[email protected]
,
Fumitaka ShiozawaDivision of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
,
Takeo IsozakiDivision of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
,
Mizuho MatsunawaDivision of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
,
Kuninobu WakabayashiDivision of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
,
Tsuyoshi OdaiDivision of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
,
Nobuyuki YajimaDivision of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
,
Yusuke MiwaDivision of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
,
Masao NegishiDivision of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
&
Hirotsugu IdeDivision of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
 show all
Pages 455-459 | Received 10 Mar 2008, Accepted 03 Apr 2008, Published online: 02 Jan 2014

References

  • Soto-Rojas AE, Kraus A. The oral side of Sjogren syndrome. Diagnosis and treatment. A review. Arch Med Res. 2002;33:95–106.
  • Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med. 2004;164: 1275–84.
  • Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL 3rd, Tran-Johnson TK, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multi-center trial. P92-01 Study Group. Arch Intern Med. 1999;159: 174–81.
  • Wall GC, Magarity ML, Jundt JW. Pharmacotherapy of xero-stomia in primary Sjogren's syndrome. Pharmacotherapy. 2002; 22:621–9.
  • Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med. 2002;162:1293–300.
  • Petrone D, Condemi JJ, Fife R, Gluck 0, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevime-fine in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002;46:748–54.
  • Ramos-Casals M, Tzioufas AG, Font J. Primary Sjogren's syn-drome: new clinical and therapeutic concepts. Ann Rheum Dis. 2005;64:347–54.
  • Iga Y, Arisawa H, Ogane N, Saito Y, Tomizuka T, Nakagawa-Yagi Y, et al. (+)-cis-2-Methylspiro[1,3-oxathiolane-5,3'-quinu-clidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol. 1998;78: 373–80.
  • Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjogren's syndrome. Clin Immunol. 2001;101:249–63.
  • Neya T, Itano N, Mizutani M, Yamasato T, Takaki M, Nakayama S. The effect of cisapride on neural 5-HT receptors in guinea-pig isolated ileum. Eur J Pharmacol. 1984;106:221–2.
  • Taniyama K, Nakayama S, Takeda K, Matsuyama S, Shirakawa J, Sano I, et al. Cisapride stimulates motility of the intestine via the 5-hydroxytryptamine receptors. J Pharmacol Exp Ther. 1991;258:1098–104.
  • Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med. 1993;329:390–5.
  • Kounenis G, Voutsas D, Koutsoviti-Papadopoulou M, Elezoglou V. Inhibition of acetylcholinesterase by the H2-receptor antago-nist nizatidine. J Pharmacobiodyn. 1988;11: 767–71.
  • Ueki S, Seiki M, Yoneta T, Aita H, Chaki K, Hon i Y, et al. Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther. 1993;264: 152–7.
  • Adachi K, Ono M, Kawamura A, Yuki M, Fujishiro H, Kinoshita Y. Nizatidine and cisapride enhance salivary secretion in humans. Aliment Pharmacol Ther. 2002;16:297–301.
  • Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alex-ander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.
  • Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum. 1985;28:1128–32.
  • Fox RI, Stern M, Michelson P. Update in Sjogren syndrome. Curr Opin Rheumatol. 2000;12:391–8.
  • Hansen A, Lipsky PE, Dorner T. New concepts in the patho-genesis of Sjogren syndrome: many questions, fewer answers. Curr Opin Rheumatol. 2003;15:563–70.
  • Sheikh SH, Shaw-Stiffel TA. The gastrointestinal manifestations of Sjogren's syndrome. Am J Gastroenterol. 1995;90:9–14.
  • Ostuni PA, Germana B, Di Mario F, Rugge M, Plebani M, De Zambiasi P, et al. Gastric involvement in primary Sjogren's syndrome. Clin Exp Rheumatol. 1993;11:21–5.
  • ter Borg EJ, Haanen HC, Haas FJ, Bistervels JH, Huisman FW, Kerckhaert JA, et al. Treatment of primary Sjogren's syndrome with fi-penicillamine: a pilot study. Neth J Med. 2002;60:402–6.
  • Drosos AA, Skopouli FN, Costopoulos JS, Papadimitriou CS, Moutsopoulos HM. Cyclosporin A (CyA) in primary Sjogren's syndrome: a double blind study. Ann Rheum Dis. 1986;45:732–5.
  • Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Meth-otrexate in primary Sjogren's syndrome. Clin Exp Rheumatol. 1996;14:555–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.